Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

Determination of Plasmatic and CSF Levels of High Doses of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

NCT03421002•Astellas Pharma Global Development, Inc.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Candidiasis, SystemicCandida Meningitis

Interventions

Micafungin

Locations

Italy

Locations (2)

Site IT39001

Rome, Italy

Site IT39002

Rome, Italy

Key Dates

Start Date

May 30, 2015

Primary Completion Date

April 10, 2018

Completion Date

April 10, 2018

Last Updated

November 18, 2024

Sponsors

Lead Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

IRCCS, Ospedale Pediatrico Bambino Gesu

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2024Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions